Tarsus Pharmaceuticals Inc expected to post a loss of 69 cents a share - Earnings Preview

Tarsus Pharmaceuticals

11/03/2023 24:53

* Tarsus Pharmaceuticals Inc  TARS.OQ   TARS.O  is expected
to show a rise in quarterly revenue when it reports  results on
March 13 (estimated). 
    * The Irvine California-based  company is expected to report
 a
2,858.6% increase in revenue to $10 million from $338 thousand a
year ago, according to the mean estimate from 3 analysts, based
on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Tarsus
Pharmaceuticals
Inc is for a loss of 69 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 7 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Tarsus
Pharmaceuticals Inc is $43​, above​ its last closing price
of $14.26. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.88       -0.97      -0.84     Beat    13.7
 Jun. 30 2022  -0.61       -0.59      -0.24     Beat    59.4
 Mar. 31 2022  -1.06       -0.92      -0.98     Missed  -6.8​
 Dec. 31 2021  -0.76       -0.73      -0.72     Beat    1
 ​​Sep.        -0.41       -0.43      -0.76     Missed  -75.1
 30 2021                                                
 Jun. 30 2021  -0.40       -0.48      0.33      Beat    169.2​
 Mar. 31 2021  -0.73       -0.64      0.47      Beat    173.4
 Dec. 31 2020              -0.66      -0.68     Missed  -3
 This summary was machine generated March 11 at 00:53 GMT.  All
figures in US dollars  unless otherwise stated